Bundamedik Tbk PT

The company maintains a debt-to-equity ratio of 0.7, indicating a relatively balanced capital structure, while its current ratio of 1.62 suggests adequate short-term liquidity to cover its obligations. However, the negative free cash flow of -81.03 billion IDR and capital expenditure of -218.91 billion IDR highlight ongoing investment in infrastructure and operations, which may pressure liquidity in the near term. Profitability metrics show a return on equity of 0.64% and a return on assets of 0.31%, both below the typical thresholds for high-performing healthcare providers. These figures suggest the company is not generating strong returns relative to its equity and asset base. The company's revenue is concentrated across its healthcare services segment, with a smaller "Others" segment contributing less to overall performance. Geographically, the company operates primarily in Indonesia, with a presence in Jakarta, Padang, Ciputat, and Bekasi. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the current or next fiscal year. This is consistent with the company's current operating performance and capital allocation strategy. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its flexibility in responding to unexpected financial demands. However, the low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders. Recent filings and transcripts have not revealed any material events or strategic shifts that would significantly alter the company's financial or operational outlook. The company continues to focus on its core hospital management and healthcare services.